In addition, WGS is able to detect lesions not routinely investigated in SoC (primary class-defining aberrations in the majority of B-other ALL samples including DUX4-r) and to allocate B-other ALL patients to one of the emerging genetic subgroups. The gene discussed is DUX4; the disease is acute lymphoblastic leukemia.